NCT00813904View on ClinicalTrials.gov

Immunogenicity and Safety Study of rThrombin in Surgical Hemostasis

PHASE4CompletedINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

January 31, 2009

Primary Completion Date

July 31, 2010

Study Completion Date

July 31, 2010

Conditions
Blood Loss, Surgical
Interventions
BIOLOGICAL

rThrombin, 1000 IU/mL

At least 1 application of reconstituted rThrombin, 1000 IU/mL, applied topically directly to the bleeding site, per product labeling.

Trial Locations (1)

85712

Tuscon Orthopaedic Institute, Tuscon

Sponsors

Lead Sponsor

ZymoGenetics
All Listed Sponsors
lead

ZymoGenetics

INDUSTRY

NCT00813904 - Immunogenicity and Safety Study of rThrombin in Surgical Hemostasis | Biotech Hunter | Biotech Hunter